Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial - Concepedia

Concepedia

Publication | Open Access

Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial

DOI Full Paper Access

14

Citations

0

References

2020

Year

Daniel M. Geynisman, Brian T. Kadow, Brian Shuch, Stephen A. Boorjian, Surena F. Matin, Edward N. Rampersaud, Barton N. Milestone, Elizabeth R. Plimack, Matthew R. Zibelman, Alexander Kutikov,

The Journal of Urology

Abstract

Everolimus was effective in causing volumetric reduction of angiomyolipomas by 25% or greater in most patients but was associated with a high rate of treatment discontinuation.